Avalyn Pharma, Inc. (AVLN)
26.04
-1.21
(-4.44%)
USD |
NASDAQ |
Oct 23, 16:00
26.04
0.00 (0.00%)
After-Hours: 19:12
Avalyn Pharma Debt to Equity Ratio : 0.043 for June 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.043 |
| Date | Value |
|---|---|
| March 31, 2026 | 0.152 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Filana Therapeutics, Inc. | 0.00 |
| CorMedix, Inc. | 0.315 |
| Eloxx Pharmaceuticals, Inc. | 0.00 |
| Breakthrough Chemistry, Inc. | 0.2335 |
| BioStem Technologies, Inc. | 0.0443 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 425.45M |
| Total Liabilities (Quarterly) | 27.10M |
| Shareholders Equity (Quarterly) | 398.35M |
| Current Ratio | 33.10 |
| Net Debt Paydown Yield | -0.20% |